Table I.
RNA and protein levels of XPA and corresponding IC50 for cisplatin in lung cancer cell lines
| Cell line | XPA level (fold elevation) | IC50 for cisplatin (μM)c | |
| RNAa | Proteinb | ||
| Calu6 | 3.1 ± 0.4 | 3.1 | 4.0 ± 0.6 |
| H23 | 3.2 ± 0.2 | 3.1 | 5.2 ± 0.7 |
| SK-LU-1 | 3.3 ± 0.3 | 3.3 | 2.7 ± 0.4 |
| HCC4006 | 2.6 ± 0.4 | 6.1 | 22.0 ± 5.5 |
| H2009 | 2.7 ± 0.2 | 9.9 | 29.0 ± 0.6 |
| H2023 | 6.7 ± 0.9 | 8.8 | 24.3 ± 5.2 |
| H2085 | 3.5 ± 0.9 | 7.1 | 16.2 ± 4.0 |
| H2228 | 1.9 ± 0.1 | 6.6 | 8.5 ± 2.8 |
| H358 | 5.8 ± 0.7 | 7.6 | 11.2 ± 1.3 |
| H441 | 4.4 ± 0.9 | 6.0 | 12.5 ± 0.5 |
| H552 | 5.3 ± 0.7 | 8.3 | 18.8 ± 1.6 |
a
Values for RNA levels are mean ± standard deviation from three separate RT-qPCR experiments that were normalized to β-actin and expressed as fold elevation compared with average expression seen for NHBEC, HBEC1 and HBEC2.
b
Values are fold elevation in protein levels relative to average levels for NHBEC, HBEC1 and HBEC2 after normalization to β-actin.
c
Values are the mean ± standard deviation for three separate determination of IC50.